Stockreport

BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, tw [Read more]